source
- Tango Therapeutics reports 82% response rate for vopimetostat plus Rasonque in pancreatic cancer, down from 92% earlierTango Therapeutics announced updated data from its ongoing Phase 1/2 trial combining its PRMT5 inhibitor vopimetostat with Revolution Medicines' newly approved drug Rasonque (daraxonrasib) in secon…
- Personalized mRNA vaccine cuts melanoma recurrence risk by 42% in trialA recent study of a personalized mRNA cancer vaccine showed a 42% reduction in disease recurrence for patients with melanoma compared with the standard of care. The vaccine is tailored to each pat…STAT · 17d agoPositive readoutPositive